- Page 2:
HANDBOOK OFSOPs FOR GOODCLINICAL PR
- Page 10:
About PolarisClinical Research Cons
- Page 14:
Table of ContentsMON-001.0MON-002.0
- Page 18:
Initial SubIRB MemberMinutes Templa
- Page 22:
SOP# MON-001.0CompanyEffective Date
- Page 26:
CompanyStandard Operating Procedure
- Page 30:
SOP# MON-002.0CompanyEffective Date
- Page 34:
CompanyStandard Operating Procedure
- Page 38:
SOP# MON-003.0CompanyEffective Date
- Page 42:
SOP# MON-004.0CompanyEffective Date
- Page 46:
SOP# MON-004.0CompanyEffective Date
- Page 50:
SOP# MON-005.0CompanyEffective Date
- Page 54:
SOP# MON-005.0CompanyEffective Date
- Page 58:
SOP# MON-006.0CompanyEffective Date
- Page 62:
SOP# MON-006.0CompanyEffective Date
- Page 66:
CompanyStandard Operating Procedure
- Page 70:
SOP# MON-007.0CompanyEffective Date
- Page 74:
SOP# MON-007.0CompanyEffective Date
- Page 78:
CompanyStandard Operating Procedure
- Page 82:
SOP# MON-008.0CompanyEffective Date
- Page 86:
SOP# MON-008.0CompanyEffective Date
- Page 90:
SOP# MON-009.0CompanyEffective Date
- Page 94:
SOP# MON-009.0CompanyEffective Date
- Page 98:
SOP# MON-009.0CompanyEffective Date
- Page 102:
SOP# MON-009.0CompanyEffective Date
- Page 106:
SOP# MON-009.0CompanyEffective Date
- Page 110:
SOP# MON-009.0CompanyEffective Date
- Page 114:
SOP# MON-010.0CompanyEffective Date
- Page 118:
SOP# MON-010.0CompanyEffective Date
- Page 122:
CompanyStandard Operating Procedure
- Page 126:
SOP# MON-011.0CompanyEffective Date
- Page 130:
CompanyStandard Operating Procedure
- Page 134:
SOP# MON-012.0CompanyEffective Date
- Page 138:
SOP# MON-012.0CompanyEffective Date
- Page 142:
CompanyStandard Operating Procedure
- Page 146:
CompanyStandard Operating Procedure
- Page 150:
SOP# SITE-001.0CompanyEffective Dat
- Page 154:
SOP# SITE-002.0CompanyEffective Dat
- Page 158:
SOP# SITE-002.0F. Retention of Trai
- Page 162:
SOP# SITE-003.0CompanyEffective Dat
- Page 166:
SOP# SITE-004.0CompanyEffective Dat
- Page 170:
SOP# SITE-005.0CompanyEffective Dat
- Page 174:
SOP# SITE-006.0CompanyEffective Dat
- Page 178:
SOP# SITE-006.0CompanyEffective Dat
- Page 182:
SOP# SITE-007.0CompanyEffective Dat
- Page 186:
CompanyStandard Operating Procedure
- Page 190:
SOP# SITE-008.0CompanyEffective Dat
- Page 194:
CompanyStandard Operating Procedure
- Page 198:
SOP# SITE-009.0CompanyEffective Dat
- Page 202:
SOP# SITE-009.0CompanyEffective Dat
- Page 206:
CompanyStandard Operating Procedure
- Page 210:
SOP# SITE-010.0CompanyEffective Dat
- Page 214:
CompanyStandard Operating Procedure
- Page 218:
SOP# SITE-011.0CompanyEffective Dat
- Page 222:
CompanyStandard Operating Procedure
- Page 226:
CompanyStandard Operating Procedure
- Page 230:
SOP# SITE-013.0CompanyEffective Dat
- Page 234:
SOP# SITE-013.0E. Sponsor ContactsC
- Page 238:
SOP# SITE-014.0CompanyEffective Dat
- Page 242:
SOP# SITE-014.0V. AttachmentsNoneCo
- Page 246:
SOP# IRB-001.0CompanyEffective Date
- Page 250:
CompanyStandard Operating Procedure
- Page 254:
SOP# IRB-002.0CompanyEffective Date
- Page 258:
SOP# IRB-002.0CompanyEffective Date
- Page 262:
CompanyStandard Operating Procedure
- Page 266:
SOP# IRB-003.0CompanyEffective Date
- Page 270:
SOP# IRB-003.0CompanyEffective Date
- Page 274:
SOP# IRB-004.0CompanyEffective Date
- Page 278:
CompanyStandard Operating Procedure
- Page 282:
SOP# IRB-005.0CompanyEffective Date
- Page 286:
SOP# IRB-005.0CompanyEffective Date
- Page 290:
SOP# IRB-006.0CompanyEffective Date
- Page 294:
SOP# IRB-006.0CompanyEffective Date
- Page 298:
CompanyStandard Operating Procedure
- Page 302:
SOP# IRB-007.0CompanyEffective Date
- Page 306:
SOP# IRB-008.0CompanyEffective Date
- Page 310:
CompanyStandard Operating Procedure
- Page 314:
SOP# IRB-009.0CompanyEffective Date
- Page 318:
SOP# IRB-009.0CompanyEffective Date
- Page 322:
CompanyProtocol Amendment FormProto
- Page 326:
CompanyCRF Review FormProtocol #: I
- Page 330:
CompanyDrug Dispensing LogDrug name
- Page 334:
CompanyClinical Trial Materials Dis
- Page 338:
CompanyInvestigational Product Rece
- Page 342:
CompanyScreening and Enrollment Log
- Page 346:
CompanyExpedited Review FormStudy I
- Page 350:
CompanySubject Information and Cons
- Page 354:
CompanySubject Information and Cons
- Page 358:
CompanyStudy Initiation Document Tr
- Page 362:
CompanyInitial Submission Form (con
- Page 366:
CompanyInitial Submission Form (con
- Page 370:
CompanyInitial Submission Form (con
- Page 374: CompanyIRB Membership RosterMultipl
- Page 378: CompanyRecommendations (number the
- Page 382: CompanyThe meeting adjourned at --:
- Page 386: CompanyMaster Subject LogProtocol #
- Page 390: CompanyTelephone Contact ReportDate
- Page 394: CompanyIRB Progress Report Form (co
- Page 398: CompanyStaff Member’s Name(Please
- Page 402: CompanyReviewer’s Checklist (cont
- Page 406: CompanySerious Adverse Subject Init
- Page 410: CompanySerious Adverse Subject Init
- Page 414: CompanySerious Adverse Subject Init
- Page 418: CompanyStudy Site Personnel Signatu
- Page 422: CompanyIRB Study Termination Acknow
- Page 428: CompanyTraining Plan FormEmployee:S
- Page 432: CompanyEmployeeProject-specific tra
- Page 436: CompanyStaff Training Request FormE
- Page 440: CompanySite Evaluation Visit Trip R
- Page 444: CompanyOverall Assessment (continue
- Page 448: CompanyMEETING CONTENTINDICATE WHIC
- Page 452: CompanyPeriodic Site Visit Trip Rep
- Page 456: CompanySERIOUS ADVERSE EXPERIENCESS
- Page 460: CompanyStudy Termination Visit Trip
- Page 464: CompanyStudy Drug (continued)Yes No
- Page 468: CompanyMeeting with InvestigatorDid